Pfizer Explores Treatments for Cachexia in Chronically Ill Patients
Pharmaceutical giant Pfizer is investigating treatments for cachexia, a debilitating syndrome causing muscle and fat loss in patients with chronic diseases, including cancer. The focus is on improving patient quality of life.
Pfizer Inc. is actively researching treatments for cachexia, a complex wasting disorder that affects patients with chronic illnesses such as cancer and heart failure. This condition, characterized by significant loss of muscle and fat, is a contributing factor to death in an estimated 20-40 percent of cancer patients.
The company's scientists aim to identify therapeutic strategies that can improve the quality of life for patients suffering from chronic conditions. Bei Zhang, Pfizer's Vice President of Worldwide Research and Development, highlighted the significant unmet medical need, noting the current absence of any medicine to treat cachexia.
Clinically, cachexia is defined by a loss of 5 percent or more of body weight within 12 months, accompanied by reduced muscle strength, fatigue, decreased appetite, and detected inflammatory biomarkers. Insights gathered from patients and caregivers are guiding the development of clinically impactful endpoints for potential therapies.
Researchers are increasingly studying cachexia as a distinct disorder driven by inflammation and metabolic imbalances. Danna Breen, a Senior Principal Scientist at Pfizer, explains that tackling this complex condition benefits from a multidisciplinary approach, involving experts in oncology, muscle biology, and metabolism.
Pfizer scientists hope that developing a cachexia treatment could allow patients to tolerate other therapies, such as cancer treatments, for longer periods, potentially improving survival chances. The ultimate goal is to restore normal metabolism and help patients maintain muscle mass, thereby extending life and significantly enhancing their quality of life.